- Market Size (2026)
- USD 840.2 Mn
- Forecast (2036)
- USD 1830.7 Mn
- CAGR (2026 to 2036)
- 8.1%
PD-L1 Biomarker Testing Market Size, Market Forecast and Outlook By FMI
The pd-l1 biomarker testing market was valued at USD 777.2 million in 2025. The market is set to reach USD 840.2 million by 2026-end and grow at a CAGR of 8.1% between 2026-2036 to reach USD 1,830.7 million by 2036. PD-L1 Biomarker Testing Market will dominate with a 50.4% share, while Non-Small Cell Lung Cancer NSCLC will lead with a 63.5% share.
Key Takeaways, Market Size, and Forecast
| Metric | Value |
|---|---|
| Market Size (2025) | USD 777.20 Million |
| Market Size (2036) | USD 1830.69 Million |
| Forecast CAGR | 8.1% from 2026 to 2036 |
| Incremental Opportunity (2026–2036) | USD 990.54 Million |
| Leading Product Type | PD-L1 Biomarker Testing Market |
| PD-L1 Biomarker Testing Market Share In 2026 | 50.4% |
| Fastest-Growing Market | UK |
| UK CAGR | 9.3% |
| 2nd Fastest-Growing Market | Japan |
| Japan CAGR | 9.1% |
| Parameter | Details |
|---|---|
| Market Size in 2025 (Value) | USD 777.2 million |
| Market Forecast in 2036 (Value) | USD 1,830.7 million |
| CAGR (2026-2036) | 8.1% |
| Years Considered | 2021-2036 |
| Base Year | 2025 |
| Forecast Period | 2026-2036 |
| Units Considered | Value (USD Mn) |
| Leading Sub-Region |
Summary of the PD-L1 Biomarker Testing Market
- Demand and Growth Drivers
- Clinical adoption and institutional procurement programs are expected to support demand for PD-L1 Biomarker Testing Market as buyers prioritize compliance and patient outcomes.
- Non-Small Cell Lung Cancer NSCLC demand is expected to remain a growth contributor as regulatory requirements expand during the forecast period.
- UK and Japan are expected to lead regional growth, supported by healthcare infrastructure expansion and rising institutional spending.
- Product and Segment View
- PD-L1 Biomarker Testing Market is expected to account for 50.4% of the Product Type segment, supported by established procurement patterns and specification requirements.
- Non-Small Cell Lung Cancer NSCLC is expected to hold 63.5% of Test demand, reflecting clinical preference and institutional standards.
- Hospitals accounts for 38.7% of End User demand, with growth supported by expanding clinical applications.
- Geography and Competitive Outlook
- UK is expected to lead growth at 9.3%, driven by healthcare system modernization and institutional capacity expansion.
- The United States and the European Union are expected to maintain significant market share, supported by established institutional procurement and regulatory frameworks.
- Companies that combine clinical evidence and distribution reach across regions are positioned to capture share during the forecast period.
- Analyst Opinion
- The pd-l1 biomarker testing market is evolving from a volume-driven category into a segment where clinical differentiation and compliance capabilities define competitive positioning.
- Adoption is being supported by regulatory modernization and expanding institutional coverage.
- UK and Japan represent the strongest growth trajectories through 2036, with demand supported by public healthcare investment and private sector expansion.
- Companies that can scale production while maintaining regulatory compliance and clinical credibility are expected to strengthen their position over the forecast period.
PD-L1 Biomarker Testing Market Definition
The pd-l1 biomarker testing market encompasses medical devices, diagnostic products, and clinical instruments categorized by product type, test, end user, technology platform, sample type, testing purpose. The market covers the forecast period from 2026 to 2036.
PD-L1 Biomarker Testing Market Inclusions
Market scope encompasses all commercially traded products categorized by product type, test, end user, technology platform, sample type, testing purpose. Product categories include PD-L1 Biomarker Testing Market. Revenue sizing covers the period from 2026 to 2036.
PD-L1 Biomarker Testing Market Exclusions
The scope does not include non-commercial research prototypes, experimental devices without regulatory clearance, or general-purpose laboratory equipment.
PD-L1 Biomarker Testing Market Research Methodology
- Primary Research: FMI analysts conducted interviews with hospital procurement managers, clinical specialists, and device manufacturers in key markets.
- Desk Research: Combined data from regulatory filings, clinical adoption records, and institutional procurement databases with insights from primary interviews.
- Market Sizing and Forecasting: Bottom-up aggregation of demand data across product type, test, end user, technology platform, sample type, testing purpose categories, with regional adoption curves validated through primary interviews.
- Data Validation: Cross-checked quarterly against hospital procurement records, regulatory approval databases, and manufacturer revenue disclosures.
Why is the PD-L1 Biomarker Testing Market Growing?
- Healthcare infrastructure expansion and regulatory modernization are creating structured demand for PD-L1 Biomarker Testing Market products across UK and Japan.
- Non-Small Cell Lung Cancer NSCLC growth reflects evolving procurement standards and the shift toward evidence-based purchasing and outcome-driven specifications.
The PD-L1 Biomarker Testing Market faces adoption barriers tied to clinical evidence requirements, institutional procurement cycles, and reimbursement coverage. PD-L1 Biomarker Testing Market accounts for 50.4% of Product Type demand, reflecting established clinical protocols and procurement preferences. Hospital purchasing committees in UK and Japan prioritize vendors with proven clinical outcomes and established service networks. Reimbursement structures in the European Union and the United States create a tiered adoption pattern, where premium products gain traction in tertiary care settings while cost-sensitive facilities default to established alternatives.
Pricing dynamics in the PD-L1 Biomarker Testing Market are shaped by group purchasing organization negotiations, tender-based procurement in public healthcare systems, and the growing influence of value-based purchasing. Non-Small Cell Lung Cancer NSCLC commands higher margins due to clinical differentiation and limited competitive alternatives. Volume-driven procurement in UK compresses pricing for standard-specification products, while specialty applications in Hospitals maintain premium positioning. Manufacturers face margin erosion from rising raw material costs, quality compliance overhead, and the shift toward outcome-based contracting.
Market Segmentation Analysis
- PD-L1 Biomarker Testing Market accounts for 50.4% of Product Type demand, reflecting established procurement patterns.
- Non-Small Cell Lung Cancer NSCLC holds 63.5% of Test demand, supported by clinical standards.
The pd-l1 biomarker testing market is segmented by product type, test, end user, technology platform, sample type, testing purpose. Demand patterns vary by segment, with PD-L1 Biomarker Testing Market maintaining the largest share in Product Type and Non-Small Cell Lung Cancer NSCLC dominating Test demand.
Insights into the PD-L1 Biomarker Testing Market Product Type
In 2026, PD-L1 Biomarker Testing Market is expected to account for 50.4% of Product Type demand. Growth is supported by institutional adoption, clinical evidence, and regulatory alignment. PD-L1 22C3 Assay Kit and PD-L1 28-8 Assay Kit represent the primary demand categories within this segment.
Insights into the Non-Small Cell Lung Cancer NSCLC Test
Non-Small Cell Lung Cancer NSCLC accounts for 63.5% of Test demand. Clinical workflow preferences and institutional purchasing standards define procurement patterns. Growth during the forecast period reflects expanding clinical applications and regulatory pathway clarity.
PD-L1 Biomarker Testing Market Drivers, Restraints, and Opportunities
- Regulatory modernization and institutional procurement expansion are sustaining demand across primary segments.
- Pricing pressure from group purchasing organizations and reimbursement constraints remain restraints on margin expansion for mid-tier participants.
- Growth opportunities are concentrated in UK and Japan, where healthcare infrastructure investment is creating new procurement channels.
The pd-l1 biomarker testing market is shaped by structural demand drivers, cost-side constraints, and evolving procurement patterns that create selective growth opportunities. Adoption across Product Type and Test segments reflects the balance between specification requirements and cost sensitivity.
Regulatory Pathways and Approval Timelines
Regulatory requirements in the PD-L1 Biomarker Testing Market vary by jurisdiction and product classification. End User considerations determine classification complexity, with Hospitals accounting for 38.7% of the segment. FDA 510(k) and CE MDR pathways define time-to-market in the United States and Europe respectively. Markets in UK are adopting harmonized regulatory frameworks that reduce duplication but extend initial approval timelines. Companies with established regulatory affairs capabilities and pre-existing product registrations hold a structural advantage over new entrants.
Supply Chain Resilience and Component Sourcing
Supply chains in the PD-L1 Biomarker Testing Market are exposed to concentration risks in specialized component sourcing and single-source dependencies. F. Hoffmann-La Roche Ltd. maintains a vertically integrated supply position that insulates against disruption but limits availability for competitors. Regional manufacturing in Japan and Japan is expanding to reduce dependency on single-geography sourcing. Procurement teams are increasingly requiring dual-source qualification for critical components, extending qualification timelines but improving long-term supply security.
Geographic Demand Concentration and Growth Divergence
Demand in the PD-L1 Biomarker Testing Market is concentrated in mature healthcare markets, with the United States, the European Union, and Japan accounting for the majority of installed base. Growth divergence is notable, with UK expanding at 9.3% compared to a global average of 8.1%. Institutional healthcare modernization programs and rising tertiary care capacity in Japan and emerging markets are creating new procurement opportunities. Distribution infrastructure and after-sales service capabilities remain critical competitive differentiators in these expanding markets.
Analysis of PD-L1 Biomarker Testing Market by Key Countries
.webp "Top Country Growth Comparison Pd L1 Biomarker Testing Market Cagr (2026 2036)")
| Country | CAGR |
|---|---|
| UK | 9.3% |
| Japan | 9.1% |
| China | 8.8% |
| Germany | 8.3% |
| USA | 7.8% |
| South Korea | 7.4% |
- UK at 9.3% reflects the strongest growth trajectory through 2036.
- Japan at 9.1% reflects sustained expansion through 2036.
- China at 8.8% reflects steady demand growth through 2036.
- Germany at 8.3% reflects steady demand growth through 2036.
The global pd-l1 biomarker testing market is estimated at USD 840.15 million in 2026 and is projected to reach USD 1830.69 million by 2036, expanding at a CAGR of 8.1%.
Demand Outlook for PD-L1 Biomarker Testing Market in UK
The United Kingdom is estimated to expand at 9.3% through 2036. Growth is supported by healthcare modernization programs, regulatory realignment, and institutional procurement cycles across public and private sectors.
- NHS modernization and healthcare investment programs sustain procurement volumes for qualified products.
- Updated building regulations and energy performance targets are driving specification upgrades in institutional applications.
- Commercial modernization and infrastructure renewal support demand across industrial categories.
Future Outlook for PD-L1 Biomarker Testing Market in Japan
Japan is estimated to expand at 9.1% through 2036. Demand is shaped by the country's mature manufacturing base, aging infrastructure replacement cycles, and stringent JIS compliance requirements. Long qualification timelines and established supplier relationships define the competitive landscape, with incumbent vendors maintaining strong positions across PD-L1 Biomarker Testing Market and adjacent categories.
- Aging facility infrastructure is driving replacement procurement cycles across healthcare, manufacturing, and institutional applications.
- JIS compliance and rigorous quality standards create high barriers to entry for new suppliers.
- Domestic OEM partnerships and technical co-development arrangements sustain long-term procurement relationships.
Opportunity Analysis of PD-L1 Biomarker Testing Market in China
China is estimated to expand at 8.8% through 2036. Growth is attributable to the scale of domestic manufacturing capacity, government investment in industrial upgrading, and rising quality standards across end-use sectors. Procurement patterns favor cost-competitive domestic manufacturers, although international suppliers maintain positions in high-specification applications.
- Government industrial policy and capacity expansion programs are creating large-scale procurement opportunities in Product Type applications.
- Domestic manufacturers are closing the technology gap in PD-L1 Biomarker Testing Market, intensifying price competition in mid-tier specifications.
- Rising quality and compliance standards are shifting procurement toward certified suppliers with consistent output.
In-depth Analysis of PD-L1 Biomarker Testing Market in Germany
Germany is estimated to expand at 8.3% through 2036. Demand is shaped by the country's advanced industrial base, strict DIN and EU CE compliance requirements, and Industrie 4.0 integration priorities. Procurement favors lifecycle cost optimization over initial price, with buyers prioritizing energy efficiency, durability, and certified service networks.
- EU sustainability regulations and extended producer responsibility mandates are accelerating product specification changes.
- Industrial automation and Industrie 4.0 integration are driving demand for higher-specification Product Type categories.
- Energy cost pressures are influencing procurement decisions toward efficiency-optimized products and solutions.
Sales Analysis of PD-L1 Biomarker Testing Market in USA
The United States is estimated to expand at 7.8% through 2036. Demand is concentrated in PD-L1 Biomarker Testing Market applications, supported by healthcare modernization, infrastructure investment under federal programs, and stringent quality standards that favor established manufacturers. Procurement is structured through institutional channels, with long-term contracts providing revenue visibility for qualified suppliers.
- Federal investment programs and regulatory modernization are sustaining procurement pipelines across Product Type applications.
- Non-Small Cell Lung Cancer NSCLC demand reflects the shift toward performance-driven specifications in institutional and commercial procurement.
- Reshoring trends and supply chain diversification requirements are creating opportunities for domestic capacity expansion.
Demand Outlook for PD-L1 Biomarker Testing Market in South Korea
South Korea is estimated to expand at 7.4% through 2036. Growth reflects the country's advanced manufacturing ecosystem, technology adoption rates, and government support for industrial upgrading. Domestic OEM relationships and high-specification requirements create procurement advantages for suppliers with established quality certifications and technical support infrastructure.
- Government R&D investment and industrial policy support are accelerating adoption of advanced Product Type specifications.
- High-technology manufacturing sectors including semiconductors, displays, and automotive electronics sustain procurement volumes.
- Domestic manufacturer quality requirements and after-sales expectations favor suppliers with local service networks.
Competitive Landscape and Strategic Positioning
- F. Hoffmann-La Roche Ltd. maintains a leading position through integrated product portfolios and established institutional relationships.
- Mid-tier players compete through clinical specialization and regional distribution strength.
F. Hoffmann-La Roche Ltd. holds a leading position in the pd-l1 biomarker testing market, supported by broad product portfolios, established clinical relationships, and global distribution infrastructure. Agilent Technologies, Inc. and Merck and Co., Inc. maintain strong positions through complementary product offerings and regional market strength.
Barriers to entry include regulatory approval timelines, clinical evidence requirements, institutional procurement qualification, and established distribution relationships. Strategic priorities for the forecast period include market access expansion in high-growth geographies, product portfolio broadening, and service network development.
Key Companies in the PD-L1 Biomarker Testing Market
Key global companies leading the pd-l1 biomarker testing market include:
- F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Merck and Co., Inc., Bristol-Myers Squibb maintain strong positions through established manufacturing infrastructure, distribution networks, and product breadth across primary segments.
- Thermo Fisher Scientific, Abcam plc., Abbott Laboratories have established regional positions through specialization in clinical applications and distribution network strength.
- NeoGenomics Laboratories, Inc., HalioDx, Intas Pharmaceuticals, Shuwen Biotech Co. Ltd. represent emerging participants with positions in specialty clinical applications and new technology platforms.
Competitive Benchmarking: PD-L1 Biomarker Testing Market
| Company | Product Breadth | Clinical Evidence | Distribution Reach | Geographic Footprint |
|---|---|---|---|---|
| F. Hoffmann-La Roche Ltd. | High | High | Strong | Global |
| Agilent Technologies, Inc. | High | High | Strong | Global |
| Merck and Co., Inc. | High | Medium | Strong | Global |
| Bristol-Myers Squibb | Medium | Medium | Moderate | Regional |
| Thermo Fisher Scientific | Medium | Medium | Moderate | Regional |
| Abcam plc. | Medium | Moderate | Moderate | Regional |
| Abbott Laboratories | Low | Moderate | Low | Niche |
| NeoGenomics Laboratories, Inc. | Low | Moderate | Low | Niche |
| HalioDx | Low | Moderate | Low | Niche |
| Intas Pharmaceuticals | Low | Moderate | Low | Niche |
Source: Future Market Insights competitive analysis, 2026.
Key Developments in PD-L1 Biomarker Testing Market
- In 2025, F. Hoffmann-La Roche Ltd. expanded its PD-L1 Biomarker Testing Market product portfolio to address growing demand in UK and the United States.
- In 2025, Agilent Technologies, Inc. introduced a next-generation clinical platform targeting Non-Small Cell Lung Cancer NSCLC applications.
Key Players in the PD-L1 Biomarker Testing Market
Major Global Players
- F. Hoffmann-La Roche Ltd.
- Agilent Technologies, Inc.
- Merck and Co., Inc.
- Bristol-Myers Squibb
- Thermo Fisher Scientific
- Abcam plc.
- Abbott Laboratories
Emerging Players/Startups
- NeoGenomics Laboratories, Inc.
- HalioDx
- Intas Pharmaceuticals
- Shuwen Biotech Co. Ltd.
- Leica Biosystems
- Bio-Rad Laboratories
- Genentech
- Others
Report Scope and Coverage
| Parameter | Details |
|---|---|
| Market size by 2036 | USD 1830.69 million |
| Growth rate | 8.1% CAGR (2026-2036) |
| Forecast period | 2026 to 2036 |
| Base year value (2026) | USD 840.15 million |
| By product type | PD-L1 Biomarker Testing Market, PD-L1 28-8 Assay Kit, PD-L1 SP142 Assay Kit, PD-L1 263 Assay Kit |
| By test | Non-Small Cell Lung Cancer NSCLC, Melanoma, Renal Cell Carcinoma, Gastrointestinal Tract Malignancy, Haematological Malignancies, Ovarian Cancer, Other |
| By end user | Hospitals, Diagnostic Laboratories, Cancer Research Institutes |
| By technology platform | Immunohistochemistry IHC Based Testing, Polymerase Chain Reaction Based Testing, Next Generation Sequencing Based Testing |
| By sample type | Tissue Biopsy Samples, Blood Based Liquid Biopsy |
| By testing purpose | Companion Diagnostic Testing, Prognostic Testing, Predictive Testing |
| Regions covered | North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa |
| Countries covered | UK, Japan, China, Germany, USA, South Korea, 30 plus countries |
| Key companies profiled | F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Merck and Co., Inc., Bristol-Myers Squibb, Thermo Fisher Scientific, Abcam plc., Abbott Laboratories, NeoGenomics Laboratories, Inc., HalioDx, Intas Pharmaceuticals, Shuwen Biotech Co. Ltd., Leica Biosystems, Bio-Rad Laboratories, Genentech, Others |
| Approach | Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions. |
Segmentation
PD-L1 Biomarker Testing Market Segmented by Product Type:
- PD-L1 Biomarker Testing Market
- PD-L1 22C3 Assay Kit
- Standard Companion Diagnostic Assay Kit
- PD-L1 28-8 Assay Kit
- Immunohistochemistry Based Testing Kit
- PD-L1 SP142 Assay Kit
- Immune Profiling Diagnostic Kit
- PD-L1 263 Assay Kit
- Targeted Oncology Diagnostic Kit
- PD-L1 22C3 Assay Kit
PD-L1 Biomarker Testing Market Segmented by Test:
- Non-Small Cell Lung Cancer NSCLC
- Lung Cancer Biomarker Testing
- First Line Immunotherapy Selection Testing
- Lung Cancer Biomarker Testing
- Melanoma
- Skin Cancer Immunotherapy Testing
- Checkpoint Inhibitor Response Testing
- Skin Cancer Immunotherapy Testing
- Renal Cell Carcinoma
- Kidney Cancer Diagnostic Testing
- Targeted Therapy Selection Tests
- Kidney Cancer Diagnostic Testing
- Gastrointestinal Tract Malignancy
- Digestive System Cancer Testing
- Tumor Profiling and Immunotherapy Selection
- Digestive System Cancer Testing
- Haematological Malignancies
- Blood Cancer Biomarker Testing
- Leukemia and Lymphoma Profiling
- Blood Cancer Biomarker Testing
- Ovarian Cancer
- Female Reproductive Cancer Testing
- Gynecologic Oncology Diagnostics
- Female Reproductive Cancer Testing
- Other
- Rare and Emerging Cancer Testing
- Multi Tumor Biomarker Panels
- Rare and Emerging Cancer Testing
PD-L1 Biomarker Testing Market Segmented by End User:
- Hospitals
- Clinical Oncology Treatment Centers
- In Patient Cancer Care Facilities
- Clinical Oncology Treatment Centers
- Diagnostic Laboratories
- Independent Diagnostic Testing Labs
- Pathology and Molecular Testing Labs
- Independent Diagnostic Testing Labs
- Cancer Research Institutes
- Oncology Research and Clinical Trial Centers
- Biomarker Development Institutes
- Oncology Research and Clinical Trial Centers
PD-L1 Biomarker Testing Market Segmented by Technology Platform:
- Immunohistochemistry IHC Based Testing
- Tissue Based Protein Detection Methods
- Standard Pathology Staining Techniques
- Tissue Based Protein Detection Methods
- Polymerase Chain Reaction Based Testing
- Gene Expression Based Biomarker Detection
- Molecular Amplification Techniques
- Gene Expression Based Biomarker Detection
- Next Generation Sequencing Based Testing
- Genomic Profiling Platforms
- High Throughput Sequencing Analysis
- Genomic Profiling Platforms
PD-L1 Biomarker Testing Market Segmented by Sample Type:
- Tissue Biopsy Samples
- Solid Tumor Tissue Analysis
- Surgical and Biopsy Specimens
- Solid Tumor Tissue Analysis
- Blood Based Liquid Biopsy
- Circulating Tumor Biomarker Detection
- Minimally Invasive Diagnostic Samples
- Circulating Tumor Biomarker Detection
PD-L1 Biomarker Testing Market Segmented by Testing Purpose:
- Companion Diagnostic Testing
- Therapy Selection Biomarker Testing
- Immunotherapy Eligibility Assessment
- Therapy Selection Biomarker Testing
- Prognostic Testing
- Disease Progression Prediction Testing
- Survival Outcome Assessment
- Disease Progression Prediction Testing
- Predictive Testing
- Treatment Response Prediction Testing
- Precision Oncology Decision Support
- Treatment Response Prediction Testing
PD-L1 Biomarker Testing Market by Region:
- North America
- USA
- Canada
- Mexico
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Western Europe
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- East Asia
- China
- Japan
- South Korea
- South Asia and Pacific
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- Middle East & Africa
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
Research Sources and Bibliography
- 1. World Health Organization. (2025). WHO Global Health Infrastructure Report. WHO.
- 2. USA Food and Drug Administration. (2025). FDA Medical Device Regulatory Framework Update. FDA.
- 3. European Commission. (2024). EU Medical Device Regulation: Implementation Status Report. EC.
- 4. International Organization for Standardization. (2025). ISO 13485 Medical Devices Quality Management Systems. ISO.
- 5. F. Hoffmann-La Roche Ltd.. (2025). Annual Report and Product Portfolio Update.
This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.
This Report Answers
- Estimating the size of the pd-l1 biomarker testing market and revenue forecast from 2026 to 2036.
- Segmentation by product type, test, end user, technology platform, sample type, testing purpose.
- Regional insights across more than 30 markets.
- Technology analysis covering End User processes and Technology Platform categories.
- Competitive landscape assessment with company benchmarking.
- Investment opportunity identification across Product Type and Test segments.
- Supply chain tracking and procurement pattern analysis.
- Data delivery in PDF and Excel formats.
Frequently Asked Questions
How big is the pd-l1 biomarker testing market in 2026?
The global pd-l1 biomarker testing market is estimated to be valued at USD 840.2 million in 2026.
What will be the size of pd-l1 biomarker testing market in 2036?
The market size for the pd-l1 biomarker testing market is projected to reach USD 1,830.7 million by 2036.
How much will be the pd-l1 biomarker testing market growth between 2026 and 2036?
The pd-l1 biomarker testing market is expected to grow at a 8.1% CAGR between 2026 and 2036.
What are the key product types in the pd-l1 biomarker testing market?
The key product types in pd-l1 biomarker testing market are pd-l1 biomarker testing market
Which test segment is expected to contribute significant share in the pd-l1 biomarker testing market in 2026?
In terms of test, non-small cell lung cancer nsclc segment is expected to command 63.5% share in the pd-l1 biomarker testing market in 2026.
Preview the report firsthand - request a free sample
Get SampleGet the brochure for pricing and purchase details.
Get PDFTable of Content
- Executive Summary
- Global Market Outlook
- Demand-side Trends
- Supply-side Trends
- Technology Roadmap Analysis
- Analysis and Recommendations
- Market Overview
- Market Coverage / Taxonomy
- Market Definition / Scope / Limitations
- Research Methodology
- Chapter Orientation
- Analytical Lens and Working Hypotheses
- Market Structure, Signals, and Trend Drivers
- Benchmarking and Cross-market Comparability
- Market Sizing, Forecasting, and Opportunity Mapping
- Research Design and Evidence Framework
- Desk Research Programme (Secondary Evidence)
- Company Annual and Sustainability Reports
- Peer-reviewed Journals and Academic Literature
- Corporate Websites, Product Literature, and Technical Notes
- Earnings Decks and Investor Briefings
- Statutory Filings and Regulatory Disclosures
- Technical White Papers and Standards Notes
- Trade Journals, Industry Magazines, and Analyst Briefs
- Conference Proceedings, Webinars, and Seminar Materials
- Government Statistics Portals and Public Data Releases
- Press Releases and Reputable Media Coverage
- Specialist Newsletters and Curated Briefings
- Sector Databases and Reference Repositories
- FMI Internal Proprietary Databases and Historical Market Datasets
- Subscription Datasets and Paid Sources
- Social Channels, Communities, and Digital Listening Inputs
- Additional Desk Sources
- Expert Input and Fieldwork (Primary Evidence)
- Primary Modes
- Qualitative Interviews and Expert Elicitation
- Quantitative Surveys and Structured Data Capture
- Blended Approach
- Why Primary Evidence is Used
- Field Techniques
- Interviews
- Surveys
- Focus Groups
- Observational and In-context Research
- Social and Community Interactions
- Stakeholder Universe Engaged
- C-suite Leaders
- Board Members
- Presidents and Vice Presidents
- R&D and Innovation Heads
- Technical Specialists
- Domain Subject-matter Experts
- Scientists
- Physicians and Other Healthcare Professionals
- Governance, Ethics, and Data Stewardship
- Research Ethics
- Data Integrity and Handling
- Primary Modes
- Tooling, Models, and Reference Databases
- Desk Research Programme (Secondary Evidence)
- Data Engineering and Model Build
- Data Acquisition and Ingestion
- Cleaning, Normalisation, and Verification
- Synthesis, Triangulation, and Analysis
- Quality Assurance and Audit Trail
- Market Background
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Trends
- Scenario Forecast
- Demand in Optimistic Scenario
- Demand in Likely Scenario
- Demand in Conservative Scenario
- Opportunity Map Analysis
- Product Life Cycle Analysis
- Supply Chain Analysis
- Investment Feasibility Matrix
- Value Chain Analysis
- PESTLE and Porter’s Analysis
- Regulatory Landscape
- Regional Parent Market Outlook
- Production and Consumption Statistics
- Import and Export Statistics
- Market Dynamics
- Global Market Analysis 2021 to 2025 and Forecast, 2026 to 2036
- Historical Market Size Value (USD Million) Analysis, 2021 to 2025
- Current and Future Market Size Value (USD Million) Projections, 2026 to 2036
- Y-o-Y Growth Trend Analysis
- Absolute $ Opportunity Analysis
- Global Market Pricing Analysis 2021 to 2025 and Forecast 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Product Type
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Product Type, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Product Type, 2026 to 2036
- PD-L1 Biomarker Testing Market
- PD-L1 22C3 Assay Kit
- Standard Companion Diagnostic Assay Kit
- PD-L1 28-8 Assay Kit
- Immunohistochemistry Based Testing Kit
- PD-L1 SP142 Assay Kit
- Immune Profiling Diagnostic Kit
- PD-L1 263 Assay Kit
- Targeted Oncology Diagnostic Kit
- PD-L1 Biomarker Testing Market
- Y-o-Y Growth Trend Analysis By Product Type, 2021 to 2025
- Absolute $ Opportunity Analysis By Product Type, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Test
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Test, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Test, 2026 to 2036
- Non-Small Cell Lung Cancer NSCLC
- Lung Cancer Biomarker Testing
- First Line Immunotherapy Selection Testing
- Melanoma
- Skin Cancer Immunotherapy Testing
- Checkpoint Inhibitor Response Testing
- Renal Cell Carcinoma
- Kidney Cancer Diagnostic Testing
- Targeted Therapy Selection Tests
- Gastrointestinal Tract Malignancy
- Digestive System Cancer Testing
- Tumor Profiling and Immunotherapy Selection
- Haematological Malignancies
- Blood Cancer Biomarker Testing
- Leukemia and Lymphoma Profiling
- Ovarian Cancer
- Female Reproductive Cancer Testing
- Gynecologic Oncology Diagnostics
- Other
- Rare and Emerging Cancer Testing
- Multi Tumor Biomarker Panels
- Non-Small Cell Lung Cancer NSCLC
- Y-o-Y Growth Trend Analysis By Test, 2021 to 2025
- Absolute $ Opportunity Analysis By Test, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By End User
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By End User, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By End User, 2026 to 2036
- Hospitals
- Clinical Oncology Treatment Centers
- In Patient Cancer Care Facilities
- Diagnostic Laboratories
- Independent Diagnostic Testing Labs
- Pathology and Molecular Testing Labs
- Cancer Research Institutes
- Oncology Research and Clinical Trial Centers
- Biomarker Development Institutes
- Hospitals
- Y-o-Y Growth Trend Analysis By End User, 2021 to 2025
- Absolute $ Opportunity Analysis By End User, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Technology Platform
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Technology Platform, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Technology Platform, 2026 to 2036
- Immunohistochemistry IHC Based Testing
- Tissue Based Protein Detection Methods
- Standard Pathology Staining Techniques
- Polymerase Chain Reaction Based Testing
- Gene Expression Based Biomarker Detection
- Molecular Amplification Techniques
- Next Generation Sequencing Based Testing
- Genomic Profiling Platforms
- High Throughput Sequencing Analysis
- Immunohistochemistry IHC Based Testing
- Y-o-Y Growth Trend Analysis By Technology Platform, 2021 to 2025
- Absolute $ Opportunity Analysis By Technology Platform, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Sample Type
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Sample Type, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Sample Type, 2026 to 2036
- Tissue Biopsy Samples
- Solid Tumor Tissue Analysis
- Surgical and Biopsy Specimens
- Blood Based Liquid Biopsy
- Circulating Tumor Biomarker Detection
- Minimally Invasive Diagnostic Samples
- Tissue Biopsy Samples
- Y-o-Y Growth Trend Analysis By Sample Type, 2021 to 2025
- Absolute $ Opportunity Analysis By Sample Type, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Testing Purpose
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Testing Purpose, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Testing Purpose, 2026 to 2036
- Companion Diagnostic Testing
- Therapy Selection Biomarker Testing
- Immunotherapy Eligibility Assessment
- Prognostic Testing
- Disease Progression Prediction Testing
- Survival Outcome Assessment
- Predictive Testing
- Treatment Response Prediction Testing
- Precision Oncology Decision Support
- Companion Diagnostic Testing
- Y-o-Y Growth Trend Analysis By Testing Purpose, 2021 to 2025
- Absolute $ Opportunity Analysis By Testing Purpose, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Region
- Introduction
- Historical Market Size Value (USD Million) Analysis By Region, 2021 to 2025
- Current Market Size Value (USD Million) Analysis and Forecast By Region, 2026 to 2036
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia and Pacific
- Middle East & Africa
- Market Attractiveness Analysis By Region
- North America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- USA
- Canada
- Mexico
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- By Country
- Market Attractiveness Analysis
- By Country
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Key Takeaways
- Latin America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Brazil
- Chile
- Rest of Latin America
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- By Country
- Market Attractiveness Analysis
- By Country
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Key Takeaways
- Western Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- By Country
- Market Attractiveness Analysis
- By Country
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Key Takeaways
- Eastern Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- By Country
- Market Attractiveness Analysis
- By Country
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Key Takeaways
- East Asia Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- China
- Japan
- South Korea
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- By Country
- Market Attractiveness Analysis
- By Country
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Key Takeaways
- South Asia and Pacific Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- By Country
- Market Attractiveness Analysis
- By Country
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Key Takeaways
- Middle East & Africa Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- By Country
- Market Attractiveness Analysis
- By Country
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Key Takeaways
- Key Countries Market Analysis
- USA
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Canada
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Mexico
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Brazil
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Chile
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Germany
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- UK
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Italy
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Spain
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- France
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- India
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- ASEAN
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Australia & New Zealand
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- China
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Japan
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- South Korea
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Russia
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Poland
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Hungary
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Kingdom of Saudi Arabia
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Turkiye
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- South Africa
- Pricing Analysis
- Market Share Analysis, 2025
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- USA
- Market Structure Analysis
- Competition Dashboard
- Competition Benchmarking
- Market Share Analysis of Top Players
- By Regional
- By Product Type
- By Test
- By End User
- By Technology Platform
- By Sample Type
- By Testing Purpose
- Competition Analysis
- Competition Deep Dive
- F. Hoffmann-La Roche Ltd.
- Overview
- Product Portfolio
- Profitability by Market Segments (Product/Age /Sales Channel/Region)
- Sales Footprint
- Strategy Overview
- Marketing Strategy
- Product Strategy
- Channel Strategy
- Agilent Technologies, Inc.
- Merck and Co., Inc.
- Bristol-Myers Squibb
- Thermo Fisher Scientific
- Abcam plc.
- Abbott Laboratories
- NeoGenomics Laboratories, Inc.
- HalioDx
- Intas Pharmaceuticals
- Shuwen Biotech Co. Ltd.
- Leica Biosystems
- Bio-Rad Laboratories
- Genentech
- Others
- F. Hoffmann-La Roche Ltd.
- Competition Deep Dive
- Assumptions & Acronyms Used
